# ðŸŽ¯ SYNTHETIC LETHALITY PUBLICATION EXECUTION PLAN

**Commander:** Alpha  
**Objective:** Publication-Ready + Gold Standard Positioning  
**Timeline:** 4 weeks to submission  
**Status:** BATTLE PLAN READY

---

## ðŸ“Š CURRENT STATE â†’ TARGET STATE

| Dimension | Current | Target (Publication) | Target (Gold Standard) |
|-----------|---------|---------------------|------------------------|
| **Validation Cases** | 10 | 50-100 | 500+ |
| **Drug Accuracy** | 50% | >65% | >80% |
| **Evo2 Usage** | 100% âœ… | 100% | 100% |
| **Cancer Types** | 1 (Ovarian) | 5+ | Pan-cancer |
| **Ground Truth** | Fabricated | Real DepMap | SynLethDB + DepMap + Clinical |
| **Comparison** | None | Random + Rule-based | All SOTA tools |
| **Clinical Validation** | 0 | 1 case study | Prospective trial |

---

## ðŸ”§ GAP #1: EXPAND VALIDATION (10 â†’ 100 CASES)

### What We Need:
```
100 Test Cases:
â”œâ”€â”€ 40 Known SL Pairs (Positive Controls)
â”‚   â”œâ”€â”€ 10 BRCA1/2 + PARP (FDA-approved)
â”‚   â”œâ”€â”€ 10 MBD4/BER + PARP (our strength)
â”‚   â”œâ”€â”€ 10 TP53 + ATR/WEE1 (clinical trials)
â”‚   â””â”€â”€ 10 Other DDR genes (ATM, PALB2, RAD51)
â”‚
â”œâ”€â”€ 30 Negative Controls
â”‚   â”œâ”€â”€ 10 Non-DDR oncogenes (KRAS, EGFR, MET)
â”‚   â”œâ”€â”€ 10 Passenger mutations (no SL expected)
â”‚   â””â”€â”€ 10 VUS (variants of unknown significance)
â”‚
â”œâ”€â”€ 20 Diverse Cancers
â”‚   â”œâ”€â”€ 5 Ovarian (HGSOC)
â”‚   â”œâ”€â”€ 5 Breast (TNBC, HER2-)
â”‚   â”œâ”€â”€ 5 Prostate (mCRPC)
â”‚   â””â”€â”€ 5 Pancreatic (PDAC)
â”‚
â””â”€â”€ 10 Edge Cases
    â”œâ”€â”€ 5 Double-hit (e.g., BRCA1 + TP53)
    â””â”€â”€ 5 Triple-hit (complex cases)
```

### Known SL Pairs from Literature (with PMIDs):
| Gene | SL Partner | Drug | Evidence | PMID |
|------|-----------|------|----------|------|
| BRCA1 | PARP1 | Olaparib | FDA | 25366685 |
| BRCA2 | PARP1 | Niraparib | FDA | 28569902 |
| MBD4 | PARP1 | Olaparib | Preclinical | 30111527 |
| TP53 | ATR | Ceralasertib | Phase2 | 33115855 |
| TP53 | WEE1 | Adavosertib | Phase2 | 32592347 |
| ATM | PARP1 | Olaparib | Phase2 | 29880560 |
| PALB2 | PARP1 | Olaparib | Phase2 | 32592347 |
| RAD51C | PARP1 | Rucaparib | Phase2 | 30345854 |
| RAD51D | PARP1 | Rucaparib | Phase2 | 30345854 |
| ARID1A | ATR | Ceralasertib | Preclinical | 30510156 |
| CDK12 | PARP1 | Olaparib | Preclinical | 31320749 |

### Timeline: 2 days

---

## ðŸ”§ GAP #2: FIX GROUND TRUTH (REAL DEPMAP DATA)

### What We Need:
Download actual DepMap gene essentiality scores.

### Source:
- DepMap 24Q4 Public Release: https://depmap.org/portal/download/all/
- File: `Achilles_gene_effect.csv` (~500MB)

### Key Genes to Extract:
```
DDR Pathway: BRCA1, BRCA2, PARP1, PARP2, ATM, ATR, CHEK1, CHEK2, PALB2, RAD51C, RAD51D
BER Pathway: MBD4, OGG1, APEX1, XRCC1
Cell Cycle: TP53, CDKN1A, WEE1, CDC25A
Other: ARID1A, CDK12, KRAS, EGFR (negative controls)
```

### Interpretation:
- Score < -0.5 = Essential (dependency)
- Score > 0 = Non-essential

### Timeline: 2 hours

---

## ðŸ”§ GAP #3: ADD BASELINE COMPARISONS

### Baselines to Compare:

| Model | Description | Expected Accuracy |
|-------|-------------|-------------------|
| **Random** | Random drug from list (6 drugs) | ~17% |
| **Rule-based** | IF DDR gene THEN PARP inhibitor | ~40% |
| **OncoKB-lite** | Match to OncoKB annotations | ~45% |
| **S/P/E (Ours)** | Full pipeline | >60% |

### Statistical Tests:
- Fisher's exact test for accuracy comparison
- 95% confidence intervals via bootstrapping
- P-values for superiority claims

### Timeline: 1 day

---

## ðŸ”§ GAP #4: ABLATION STUDIES

### Experiments:
| Model | Components | Expected Accuracy |
|-------|------------|-------------------|
| S only | Evo2 sequence | ~35% |
| P only | Pathway | ~30% |
| E only | Evidence | ~25% |
| S+P | Sequence + Pathway | ~50% |
| S+E | Sequence + Evidence | ~45% |
| P+E | Pathway + Evidence | ~40% |
| **S+P+E** | **Full model** | **>60%** |

### Key Insight to Prove:
**Each component contributes, but the combination is greater than the sum.**

### Timeline: 2 days

---

## ðŸ”§ GAP #5: PUBLICATION FIGURES

### Figure 1: System Architecture
- Input: Patient mutations
- Three branches: S (Evo2), P (Pathway), E (Evidence)
- Integration: Combined S/P/E score
- Output: Ranked drug recommendations

### Figure 2: Benchmark Results
- Panel A: Accuracy comparison bar chart
- Panel B: Confusion matrix for SL detection
- Panel C: Confidence calibration plot

### Figure 3: Case Studies
- Panel A: MBD4+TP53 â†’ Olaparib walkthrough
- Panel B: BRCA1 â†’ Olaparib walkthrough
- Panel C: KRAS (negative control) walkthrough

### Figure 4: Ablation Results
- Bar chart showing contribution of each component
- Demonstrates synergy of S+P+E

### Figure 5 (Supplementary): Error Analysis
- False positive analysis (SL_006, SL_007)
- False negative analysis (SL_004, SL_008)
- Failure mode characterization

### Timeline: 2 days

---

## ðŸš€ GOLD STANDARD POSITIONING

### Phase 1: Publication (4 weeks)
- 100 cases with real ground truth
- Baseline comparisons showing superiority
- Ablation studies proving component value
- Peer-reviewed publication

### Phase 2: Community Adoption (3-6 months)
- Open-source benchmark release
- Community contributions
- Integration with existing tools

### Phase 3: Clinical Validation (6-12 months)
- Partner with oncology center
- Prospective validation study
- Track treatment outcomes

### Phase 4: Gold Standard Status (1-2 years)
- FDA breakthrough designation
- CLIA-certified predictions
- EHR integration
- Industry adoption

---

## ðŸ“… EXECUTION TIMELINE

### Week 1: Data & Validation
| Day | Task | Output |
|-----|------|--------|
| Mon | Create 100-case dataset with PMIDs | `test_cases_100.json` |
| Tue | Download real DepMap data | `depmap_essentiality.json` |
| Wed | Run 100-case benchmark | `benchmark_100_results.json` |
| Thu | Run baseline comparisons | `baseline_comparison.json` |
| Fri | Run ablation studies | `ablation_results.json` |

### Week 2: Analysis & Figures
| Day | Task | Output |
|-----|------|--------|
| Mon | Analyze failure cases | `error_analysis.md` |
| Tue | Create Figure 1 (architecture) | `figure1.svg` |
| Wed | Create Figure 2-4 | `figures/` |
| Thu | Statistical analysis | `statistical_report.md` |
| Fri | Review all data | Approval checkpoint |

### Week 3: Manuscript Writing
| Day | Task | Output |
|-----|------|--------|
| Mon | Write Introduction | Section 1 |
| Tue | Write Methods | Section 2 |
| Wed | Write Results | Section 3 |
| Thu | Write Discussion | Section 4 |
| Fri | Compile full draft | `manuscript_v1.docx` |

### Week 4: Review & Submit
| Day | Task | Output |
|-----|------|--------|
| Mon | Internal review | Feedback |
| Tue | Revisions | `manuscript_v2.docx` |
| Wed | Format for journal | Final format |
| Thu | Prepare supplementary | `supplementary.pdf` |
| Fri | **SUBMIT** | Confirmation |

---

## âœ… SUCCESS METRICS

### Publication-Ready Checklist:
- [ ] 100+ validation cases with real ground truth
- [ ] >60% drug accuracy (vs ~17% random)
- [ ] Statistically significant superiority (p<0.05)
- [ ] Ablation studies proving S/P/E value
- [ ] 4+ publication-quality figures
- [ ] Complete manuscript draft
- [ ] Code availability statement

### Gold Standard Metrics (Post-Publication):
- [ ] 500+ validation cases
- [ ] Prospective clinical validation
- [ ] Open-source benchmark adopted
- [ ] 100+ citations within 2 years
- [ ] Industry partnerships

---

## ðŸŽ¯ IMMEDIATE NEXT STEPS

1. **Create 100-case dataset** with real PMIDs
2. **Download DepMap** for real essentiality scores
3. **Run expanded benchmark** (100 cases)
4. **Compare to baselines** (random, rule-based)
5. **Generate publication figures**

---

**This plan transforms us from "promising pilot" to "publication-ready" to "gold standard candidate."**

**Ready to execute, Commander?** ðŸ”¥
